Based on the growing credibility of IMH within the medical community, there is now physician demand for additional new products. R&D investments by IMH are now being made in the following pipeline:

IBgard Jr.
For 7-14 years of age for IBS - In Development
Building off of the strong efficacy, safety and tolerability of IBgard, a more advanced formulation has been developed for pediatric patients. This formulation contains half the strength of the L- menthol found in IBgard. A confirmatory clinical trial to the Kline* study will precede the product launch, expected in 2017. Kline R, et al. J of Pediatrics 2001;138:125-8

For Diverticular Disease - In Concept
Leading physicians have commented that they have used IBgard for managing the symptoms of diverticular disease out of desperation because there is nothing else available. This disease is characterized primarily by abdominal pain which can severely impact quality of life. This is in product concept stage.

For Ulcerative Colitis - In Early Concept
Ulcerative colitis is a form of IBD (Inflammatory Bowel Disease) where the colon is susceptible to inflammation and ulcers and sometimes requires painful and life altering colon surgery. Patients who suffer from ulcerative colitis are susceptible to malabsorption of nutrients.  The IMH SST® technology is planned to be applied in this area along with a combination of well studied ingredients that can help toward managing this condition.

For Crohn's Disease - In Early Concept
Crohn's Disease is a type of IBD (Inflammatory Bowel Disease) that can affect large parts of the GI tract. Patients can suffer severe weight loss and inability to absorb essential nutrients in addition to crippling abdominal pain. For most patients, dietary changes aren't enough to relieve the symptoms of Crohn's Disease. In spite of availability of new products it remains an area of unmet need. IMH SST® technology is planned to be deployed to bring well studied ingredients to the GI tract sites where Crohn’s exists.